- Home
- NUVL vs EXLS Comparison
NUVL vs EXLS Comparison
Compare NUVL & EXLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVL
- EXLS
- Stock Information
- Founded
- NUVL 2017
- EXLS 1999
- Country
- NUVL United States
- EXLS United States
- Employees
- NUVL N/A
- EXLS N/A
- Industry
- NUVL Biotechnology: Pharmaceutical Preparations
- EXLS Business Services
- Sector
- NUVL Health Care
- EXLS Consumer Discretionary
- Exchange
- NUVL Nasdaq
- EXLS Nasdaq
- Market Cap
- NUVL 6.7B
- EXLS 7.3B
- IPO Year
- NUVL 2021
- EXLS 2006
- Fundamental
- Price
- NUVL $75.84
- EXLS $47.15
- Analyst Decision
- NUVL Strong Buy
- EXLS Strong Buy
- Analyst Count
- NUVL 11
- EXLS 8
- Target Price
- NUVL $112.36
- EXLS $42.25
- AVG Volume (30 Days)
- NUVL 558.9K
- EXLS 851.4K
- Earning Date
- NUVL 02-25-2025
- EXLS 02-27-2025
- Dividend Yield
- NUVL N/A
- EXLS N/A
- EPS Growth
- NUVL N/A
- EXLS 8.50
- EPS
- NUVL N/A
- EXLS 1.14
- Revenue
- NUVL N/A
- EXLS $1,771,004,000.00
- Revenue This Year
- NUVL N/A
- EXLS $14.68
- Revenue Next Year
- NUVL N/A
- EXLS $12.41
- P/E Ratio
- NUVL N/A
- EXLS $41.40
- Revenue Growth
- NUVL N/A
- EXLS 11.29
- 52 Week Low
- NUVL $61.80
- EXLS $28.16
- 52 Week High
- NUVL $113.51
- EXLS $47.93
- Technical
- Relative Strength Index (RSI)
- NUVL 38.09
- EXLS 64.60
- Support Level
- NUVL $69.58
- EXLS $43.68
- Resistance Level
- NUVL $78.18
- EXLS $47.14
- Average True Range (ATR)
- NUVL 3.03
- EXLS 1.01
- MACD
- NUVL 0.04
- EXLS 0.25
- Stochastic Oscillator
- NUVL 50.40
- EXLS 81.65
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
About EXLS ExlService Holdings Inc.
ExlService Holdings Inc. is a business process management company that provides digital operations and analytical services to clients driving enterprise-scale business transformation initiatives that leverage company's deep expertise in analytics, AI, ML and cloud. The company offers business process outsourcing and automation services, and data-driven insights to customers across multiple industries. The company operates through four segments based on the products and services offered and markets served: Insurance, Healthcare, Emerging, Analytics. The vast majority of the company's revenue is earned in the United States, and more than half of its revenue comes from Analytics segment.